Polymeric colloidal particulate systems: intelligent tools for intracellular targeting of antileishmanial cargos

Bibliography

• Herwaldt BL. Leishmaniasis. Lancet 1999;354(9185):1191–9
   PubMed Web of Science ®Google Scholar
• Guerin PJ, Olliaro P, Sundar S, et al. Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda. Lancet Infect Dis 2002;2(8):494–501
   PubMed Web of Science ®Google Scholar
• Chappuis F, Sundar S, Hailu A, et al. Visceral leishmaniasis: what are the needs for diagnosis, treatment and control? Nat Rev Microbiol 2007;5(11):873-82
   PubMed Web of Science ®Google Scholar
• Maltezou HC. Drug resistance in visceral leishmaniasis. J Biomed Biotechnol 2010;2010:617521
   PubMedGoogle Scholar
• El-On J. Current status and perspectives of the immunotherapy of leishmaniasis. Isr Med Assoc J 2009;11(10):623-8
   PubMed Web of Science ®Google Scholar
• Ngouateu OB, Kollo P, Ravel C, et al. Clinical features and epidemiology of cutaneous leishmaniasis and Leishmania major/HIV co-infection in Cameroon: results of a large cross-sectional study. Trans R Soc Trop Med Hyg 2012;106(3):137-42
   PubMed Web of Science ®Google Scholar
• Cota GF, de Sousa MR, Rabello A. Predictors of visceral leishmaniasis relapse in HIV-infected patients: a systematic review. PLoS Negl Trop Dis 2011;5(6):e1153
   PubMed Web of Science ®Google Scholar
• Forrest ML, Kwon GS. Clinical developments in drug delivery nanotechnology. Adv Drug Deliv Rev 2008;60(8):861-2
   PubMed Web of Science ®Google Scholar
• Kumar N, Gupta S, Dube A, et al. Emerging role of vesicular carriers for therapy of visceral leishmaniasis: conventional versus novel. Crit Rev Ther Drug Carrier Syst 2010;27(6):461-507
   PubMed Web of Science ®Google Scholar
• Date AA, Joshi MD, Patravale VB. Parasitic diseases: liposomes and polymeric nanoparticles versus lipid nanoparticles. Adv Drug Deliv Rev 2007;59(6):505-21
   PubMed Web of Science ®Google Scholar
• Doroud D, Rafati S. Leishmaniasis: focus on the design of nanoparticulate vaccine delivery systems. Expert Rev Vaccines 2012;11(1):69-86
   PubMed Web of Science ®Google Scholar
• Gershkovich P, Sivak O, Wasan EK, et al. Biodistribution and tissue toxicity of amphotericin B in mice following multiple dose administration of a novel oral lipid-based formulation (iCo-009). J Antimicrob Chemother 2010;65(12):2610-13
   PubMed Web of Science ®Google Scholar
• Gupta S, Dube A, Vyas SP. Antileishmanial efficacy of amphotericin B bearing emulsomes against experimental visceral leishmaniasis. J Drug Target 2007;15(6):437-44
   PubMed Web of Science ®Google Scholar
• Frézard F, Demicheli C. New delivery strategies for the old pentavalent antimonial drugs. Expert Opin Drug Deliv 2010;7(12):1343-58
   PubMed Web of Science ®Google Scholar
• Alexander J, Russell DG. The interaction of Leishmania species with macrophages. Adv Parasitol 1992;31:175-254
   PubMed Web of Science ®Google Scholar
• Hammarton TC, Mottram JC, Doerig C. The cell cycle of parasitic protozoa: potential for chemotherapeutic exploitation. Prog Cell Cycle Res 2003;5:91-101
   PubMedGoogle Scholar
• Ravichandran KS, Lorenz U. Engulfment of apoptotic cells: signals for a good meal. Nat Rev Immunol 2007;7(12):964-74
   PubMed Web of Science ®Google Scholar
• Ueno N, Wilson ME. Receptor-mediated phagocytosis of Leishmania: implications for intracellular survival. Trends Parasitol 2012;28(8):335-44
   PubMed Web of Science ®Google Scholar
• Sacks D, Sher A. Evasion of innate immunity by parasitic protozoa. Nat Immunol 2002;3(11):1041-7
   PubMed Web of Science ®Google Scholar
• Naderer T, Vince JE, McConville MJ. Surface determinants of Leishmania parasites and their role in infectivity in the mammalian host. Curr Mol Med 2004;4(6):649-65
   PubMed Web of Science ®Google Scholar
• Burchmore RJ, Barrett MP. Life in vacuoles–nutrient acquisition by Leishmania amastigotes. Int J Parasitol 2001;31(12):1311-20
   PubMed Web of Science ®Google Scholar
• Wanderley JL, Moreira ME, Benjamin A, et al. Mimicry of apoptotic cells by exposing phosphatidylserine participates in the establishment of amastigotes of Leishmania (L) amazonensis in mammalian hosts. J Immunol 2006;176(3):1834-9
   PubMed Web of Science ®Google Scholar
• Yurdakul P. Immunopathogenesis of Leishmania infections. Mikrobiyol Bul 2005;39(3):363-81
   PubMedGoogle Scholar
• Bogdan C, Moll H, Solbach W, et al. Tumor necrosis factor-alpha in combination with interferon-gamma, but not with interleukin 4 activates murine macrophages for elimination of Leishmania major amastigotes. Eur J Immunol 1990;20(5):1131-5
   PubMed Web of Science ®Google Scholar
• Sacks D, Noben-Trauth N. The immunology of susceptibility and resistance to Leishmania major in mice. Nat Rev Immunol 2002;2(11):845-58
   PubMed Web of Science ®Google Scholar
• Agrawal AK, Gupta CM. Tuftsin-bearing liposomes in treatment of macrophage-based infections. Adv Drug Deliv Rev 2000;41(2):135-46
   PubMed Web of Science ®Google Scholar
• Alrajhi AA, Ibrahim EA, De Vol EB, et al. Fluconazole for the treatment of cutaneous leishmaniasis caused by Leishmania major. N Engl J Med 2002;346(12):891-5
   PubMed Web of Science ®Google Scholar
• Koutinas AF, Saridomichelakis MN, Mylonakis ME, et al. A randomised, blinded, placebo-controlled clinical trial with allopurinol in canine leishmaniosis. Vet Parasitol 2001;98(4):247-61
   PubMed Web of Science ®Google Scholar
• Martin MB, Grimley JS, Lewis JC, et al. Bisphosphonates inhibit the growth of Trypanosoma brucei, Trypanosoma cruzi, Leishmania donovani, Toxoplasma gondii, and Plasmodium falciparum: a potential route to chemotherapy. J Med Chem 2001;44(6):909-16
   PubMed Web of Science ®Google Scholar
• Lopes R, Eleuterio CV, Goncalves LM, et al. Lipid nanoparticles containing oryzalin for the treatment of leishmaniasis. Eur J Pharm Sci 2012;45(4):442-50
   PubMed Web of Science ®Google Scholar
• Tavares J, Ouaissi A, Kong Thoo Lin P, et al. Bisnaphthalimidopropyl derivatives as inhibitors of Leishmania SIR2 related protein 1. ChemMedChem 2010;5(1):140-7
   PubMed Web of Science ®Google Scholar
• Sett R, Basu N, Ghosh AK, et al. Potential of doxorubicin as an antileishmanial agent. J Parasitol 1992;78(2):350-4
   PubMed Web of Science ®Google Scholar
• Kayser O, Kiderlen AF, Bertels S, et al. Antileishmanial activities of aphidicolin and its semisynthetic derivatives. Antimicrob Agents Chemother 2001;45(1):288-92
   PubMed Web of Science ®Google Scholar
• Vale-Costa S, Vale N, Matos J, et al. Peptidomimetic and organometallic derivatives of primaquine active against Leishmania infantum. Antimicrob Agents Chemother 2012;56(11):5774-81
   PubMed Web of Science ®Google Scholar
• Murray HW, Hariprashad J. Activity of oral atovaquone alone and in combination with antimony in experimental visceral leishmaniasis. Antimicrob Agents Chemother 1996;40(3):586-7
   PubMed Web of Science ®Google Scholar
• Badaro R, Falcoff E, Badaro FS, et al. Treatment of visceral leishmaniasis with pentavalent antimony and interferon gamma. N Engl J Med 1990;322(1):16-21
   PubMed Web of Science ®Google Scholar
• Murray HW, Brooks EB, DeVecchio JL, et al. Immunoenhancement combined with amphotericin B as treatment for experimental visceral leishmaniasis. Antimicrob Agents Chemother 2003;47(8):2513-17
   PubMed Web of Science ®Google Scholar
• Convit J, Castellanos PL, Rondon A, et al. Immunotherapy versus chemotherapy in localised cutaneous leishmaniasis. Lancet 1987;1(8530):401-5
   PubMed Web of Science ®Google Scholar
• Ghose AC, Mookerjee A, Sengupta K, et al. Therapeutic and prophylactic uses of protein A in the control of Leishmania donovani infection in experimental animals. Immunol Lett 1999;65(3):175-81
   PubMed Web of Science ®Google Scholar
• Smith AC, Yardley V, Rhodes J, et al. Activity of the novel immunomodulatory compound tucaresol against experimental visceral leishmaniasis. Antimicrob Agents Chemother 2000;44(6):1494-8
   PubMed Web of Science ®Google Scholar
• Buates S, Matlashewski G. Treatment of experimental leishmaniasis with the immunomodulators imiquimod and S-28463: efficacy and mode of action. J Infect Dis 1999;179(6):1485-94
   PubMed Web of Science ®Google Scholar
• Monzote L. Current treatment of leishmaniasis: a review. Open Antimicrob Agents J 2009;1:9-19
   Google Scholar
• Croft SL, Sundar S, Fairlamb AH. Drug resistance in leishmaniasis. Clin Microbiol Rev 2006;19(1):111-26
   PubMed Web of Science ®Google Scholar
• Polonio T, Efferth T. Leishmaniasis: drug resistance and natural products (review). Int J Mol Med 2008;22(3):277-86
   PubMed Web of Science ®Google Scholar
• Coelho AC, Messier N, Ouellette M, et al. Role of the ABC transporter PRP1 (ABCC7) in pentamidine resistance in Leishmania amastigotes. Antimicrob Agents Chemother 2007;51(8):3030-2
   PubMed Web of Science ®Google Scholar
• Wyllie S, Cunningham ML, Fairlamb AH. Dual action of antimonial drugs on thiol redox metabolism in the human pathogen Leishmania donovani. J Biol Chem 2004;279(38):39925-32
   PubMed Web of Science ®Google Scholar
• Castanys-Munoz E, Alder-Baerens N, Pomorski T, et al. A novel ATP-binding cassette transporter from Leishmania is involved in transport of phosphatidylcholine analogues and resistance to alkyl-phospholipids. Mol Microbiol 2007;64(5):1141-53
   PubMed Web of Science ®Google Scholar
• Chakraborty R, Dasgupta D, Adhya S, et al. Cationic liposome-encapsulated antisense oligonucleotide mediates efficient killing of intracellular Leishmania. Biochem J 1999;340(Pt 2):393-6
   PubMed Web of Science ®Google Scholar
• Noronha FS, Cruz JS, Beirao PS, et al. Macrophage damage by Leishmania amazonensis cytolysin: evidence of pore formation on cell membrane. Infect Immun 2000;68(8):4578-84
   PubMed Web of Science ®Google Scholar
• Quintana E, Torres Y, Alvarez C, et al. Changes in macrophage membrane properties during early Leishmania amazonensis infection differ from those observed during established infection and are partially explained by phagocytosis. Exp Parasitol 2010;124(3):258-64
   PubMed Web of Science ®Google Scholar
• Lamour SD, Choi BS, Keun HC, et al. Metabolic characterization of Leishmania major infection in activated and nonactivated macrophages. J Proteome Res 2012;11(8):4211-22
   PubMed Web of Science ®Google Scholar
• Pandya S, Verma RK, Misra A. Nanoparticles containing nitric oxide donor with antileishmanial agent for synergistic effect against visceral leishmaniasis. J Biomed Nanotechnol 2011;7(1):213-15
   PubMed Web of Science ®Google Scholar
• Haldar AK, Sen P, Roy S. Use of antimony in the treatment of leishmaniasis: current status and future directions. Mol Biol Int 2011;2011:571242
   PubMedGoogle Scholar
• Rabhi I, Rabhi S, Ben-Othman R, et al. Transcriptomic signature of leishmania infected mice macrophages: a metabolic point of view. PLoS Negl Trop Dis 2012;6(8):e1763
   PubMed Web of Science ®Google Scholar
• Krauth-Siegel RL, Meiering SK, Schmidt H. The parasite-specific trypanothione metabolism of trypanosoma and leishmania. Biol Chem 2003;384(4):539-49
   PubMed Web of Science ®Google Scholar
• Price HP, Menon MR, Panethymitaki C, et al. Myristoyl-CoA:protein N-myristoyltransferase, an essential enzyme and potential drug target in kinetoplastid parasites. J Biol Chem 2003;278(9):7206-14
   PubMed Web of Science ®Google Scholar
• Croft SL, Coombs GH. Leishmaniasis–current chemotherapy and recent advances in the search for novel drugs. Trends Parasitol 2003;19(11):502-8
   PubMed Web of Science ®Google Scholar
• Devalapally H, Chakilam A, Amiji MM. Role of nanotechnology in pharmaceutical product development. J Pharm Sci 2007;96(10):2547-65
   PubMed Web of Science ®Google Scholar
• Ni F, Jiang L, Yang R, et al. Effects of PEG length and iron oxide nanoparticles size on reduced protein adsorption and non-specific uptake by macrophage cells. J Nanosci Nanotechnol 2012;12(3):2094-100
   PubMed Web of Science ®Google Scholar
• Owais M, Gupta CM. Targeted drug delivery to macrophages in parasitic infections. Curr Drug Deliv 2005;2(4):311-18
   PubMedGoogle Scholar
• Torchilin VP. Multifunctional nanocarriers. Adv Drug Deliv Rev 2006;58(14):1532-55
   PubMed Web of Science ®Google Scholar
• Werbovetz KA. Target-based drug discovery for malaria, leishmaniasis, and trypanosomiasis. Curr Med Chem 2000;7(8):835-60
   PubMed Web of Science ®Google Scholar
• Sen N, Majumder HK. Mitochondrion of protozoan parasite emerges as potent therapeutic target: exciting drugs are on the horizon. Curr Pharm Des 2008;14(9):839-46
   PubMed Web of Science ®Google Scholar
• Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov 2005;4(2):145-60
   PubMed Web of Science ®Google Scholar
• Couvreur P, Kante B, Roland M, et al. Polycyanoacrylate nanocapsules as potential lysosomotropic carriers: preparation, morphological and sorptive properties. J Pharm Pharmacol 1979;31(5):331-2
   PubMed Web of Science ®Google Scholar
• Gaspar R, Opperdoes FR, Preat V, et al. Drug targeting with polyalkylcyanoacrylate nanoparticles: in vitro activity of primaquine-loaded nanoparticles against intracellular Leishmania donovani. Ann Trop Med Parasitol 1992;86(1):41-9
   PubMed Web of Science ®Google Scholar
• Gaspar R, Preat V, Opperdoes FR, et al. Macrophage activation by polymeric nanoparticles of polyalkylcyanoacrylates: activity against intracellular Leishmania donovani associated with hydrogen peroxide production. Pharm Res 1992;9(6):782-7
   PubMed Web of Science ®Google Scholar
• Paul M, Durand R, Boulard Y, et al. Physicochemical characteristics of pentamidine-loaded polymethacrylate nanoparticles: implication in the intracellular drug release in Leishmania major infected mice. J Drug Target 1998;5(6):481-90
   PubMed Web of Science ®Google Scholar
• Fusai T, Deniau M, Durand R, et al. Action of pentamidine-bound nanoparticles against Leishmania on an in vivo model. Parasite 1994;1(4):319-24
   PubMed Web of Science ®Google Scholar
• Fusai T, Boulard Y, Durand R, et al. Ultrastructural changes in parasites induced by nanoparticle-bound pentamidine in a Leishmania major/mouse model. Parasite 1997;4(2):133-9
   PubMed Web of Science ®Google Scholar
• Durand R, Paul M, Rivollet D, et al. Activity of pentamidine-loaded methacrylate nanoparticles against Leishmania infantum in a mouse model. Int J Parasitol 1997;27(11):1361-7
   PubMed Web of Science ®Google Scholar
• Venier-Julienne MC, Vouldoukis I, Monjour L, et al. In vitro study of the anti-leishmanial activity of biodegradable nanoparticles. J Drug Target 1995;3(1):23-9
   PubMed Web of Science ®Google Scholar
• Verma RK, Pandya S, Misra A. Loading and release of amphotericin-B from biodegradable poly(lactic-co-glycolic acid) nanoparticles. J Biomed Nanotechnol 2011;7(1):118-20
   PubMed Web of Science ®Google Scholar
• Italia JL, Kumar MN, Carter KC. Evaluating the potential of polyester nanoparticles for per oral delivery of amphotericin B in treating visceral leishmaniasis. J Biomed Nanotechnol 2012;8(4):695-702
   PubMed Web of Science ®Google Scholar
• Van de Ven H, Paulussen C, Feijens PB, et al. PLGA nanoparticles and nanosuspensions with amphotericin B: potent in vitro and in vivo alternatives to Fungizone and AmBisome. J Control Release 2012;161(3):795-803
   PubMed Web of Science ®Google Scholar
• Van de Ven H, Vermeersch M, Matheeussen A, et al. PLGA nanoparticles loaded with the antileishmanial saponin beta-aescin: factor influence study and in vitro efficacy evaluation. Int J Pharm 2011;420(1):122-32
   PubMedGoogle Scholar
• Van de Ven H, Vermeersch M, Vandenbroucke RE, et al. Intracellular drug delivery in Leishmania-infected macrophages: evaluation of saponin-loaded PLGA nanoparticles. J Drug Target 2012;20(2):142-54
   PubMed Web of Science ®Google Scholar
• Roy P, Das S, Bera T, et al. Andrographolide nanoparticles in leishmaniasis: characterization and in vitro evaluations. Int J Nanomedicine 2010;5:1113-21
   PubMed Web of Science ®Google Scholar
• Lala S, Gupta S, Sahu NP, et al. Critical evaluation of the therapeutic potential of bassic acid incorporated in oil-in-water microemulsions and poly-D,L-lactide nanoparticles against experimental leishmaniasis. J Drug Target 2006;14(4):171-9
   PubMed Web of Science ®Google Scholar
• Costa Lima SA, Resende M, Silvestre R, et al. Characterization and evaluation of BNIPDaoct-loaded PLGA nanoparticles for visceral leishmaniasis: in vitro and in vivo studies. Nanomedicine (Lond) 2012;7(12):1839-49
   PubMed Web of Science ®Google Scholar
• Dutta M, Bandyopadhyay R, Basu MK. Neoglycosylated liposomes as efficient ligands for the evaluation of specific sugar receptors on macrophages in health and in experimental leishmaniasis. Parasitology 1994;109(Pt 2):139-47
   PubMedGoogle Scholar
• Nahar M, Jain NK. Preparation, characterization and evaluation of targeting potential of amphotericin B-loaded engineered PLGA nanoparticles. Pharm Res 2009;26(12):2588-98
   PubMed Web of Science ®Google Scholar
• Sharma S, Kumar P, Jaiswal A, et al. Development and characterization of doxorubicin loaded microparticles against experimental visceral leishmaniasis. J Biomed Nanotechnol 2011;7(1):135-6
   PubMed Web of Science ®Google Scholar
• Ordonez-Gutierrez L, Espada-Fernandez R, Dea-Ayuela MA, et al. In vitro effect of new formulations of amphotericin B on amastigote and promastigote forms of Leishmania infantum. Int J Antimicrob Agents 2007;30(4):325-9
   PubMed Web of Science ®Google Scholar
• Sanchez-Brunete JA, Dea MA, Rama S, et al. Influence of the vehicle on the properties and efficacy of microparticles containing amphotericin B. J Drug Target 2005;13(4):225-33
   PubMed Web of Science ®Google Scholar
• Rodrigues JM Jr, Croft SL, Fessi H, et al. The activity and ultrastructural localization of primaquine-loaded poly (d,l-lactide) nanoparticles in Leishmania donovani infected mice. Trop Med Parasitol 1994;45(3):223-8
   PubMedGoogle Scholar
• Rodrigues JM, Fessi H, Bories C, et al. Primaquine-loaded poly(lactide) nanoparticles: physicochemical study and acute tolerance in mice. Int J Pharm 1995;126(1-2):253-60
   Google Scholar
• Durand R, Paul M, Rivollet D, et al. Activity of pentamidine-loaded poly (D,L-lactide) nanoparticles against Leishmania infantum in a murine model. Parasite 1997;4(4):331-6
   PubMed Web of Science ®Google Scholar
• Costa Lima S, Rodrigues V, Garrido J, et al. In vitro evaluation of bisnaphthalimidopropyl derivatives loaded into pegylated nanoparticles against Leishmania infantum protozoa. Int J Antimicrob Agents 2012;39(5):424-30
   PubMed Web of Science ®Google Scholar
• Lala S, Nandy AK, Mahato SB, et al. Delivery in vivo of 14-deoxy-11-oxoandrographolide, an antileishmanial agent, by different drug carriers. Indian J Biochem Biophys 2003;40(3):169-74
   PubMed Web of Science ®Google Scholar
• Tyagi R, Lala S, Verma AK, et al. Targeted delivery of arjunglucoside I using surface hydrophilic and hydrophobic nanocarriers to combat experimental leishmaniasis. J Drug Target 2005;13(3):161-71
   PubMed Web of Science ®Google Scholar
• Torres-Santos EC, Rodrigues JM Jr, Moreira DL, et al. Improvement of in vitro and in vivo antileishmanial activities of 2', 6'-dihydroxy-4'-methoxychalcone by entrapment in poly(D,L-lactide) nanoparticles. Antimicrob Agents Chemother 1999;43(7):1776-8
   PubMed Web of Science ®Google Scholar
• Cauchetier E, Paul M, Rivollet D, et al. Therapeutic evaluation of free and nanocapsule-encapsulated atovaquone in the treatment of murine visceral leishmaniasis. Ann Trop Med Parasitol 2003;97(3):259-68
   PubMed Web of Science ®Google Scholar
• Heurtault B, Legrand P, Mosqueira V, et al. The antileishmanial properties of surface-modified, primaquine-loaded nanocapsules tested against intramacrophagic Leishmania donovani amastigotes in vitro. Ann Trop Med Parasitol 2001;95(5):529-33
   PubMed Web of Science ®Google Scholar
• Espuelas MS, Legrand P, Loiseau PM, et al. In vitro antileishmanial activity of amphotericin B loaded in poly(epsilon-caprolactone) nanospheres. J Drug Target 2002;10(8):593-9
   PubMed Web of Science ®Google Scholar
• Singh P, Gupta A, Jaiswal A, et al. Design and development of Amphotericin B bearing polycaprolactone microparticles for macrophage targeting. J Biomed Nanotechnol 2011;7(1):50-1
   PubMed Web of Science ®Google Scholar
• Dea-Ayuela MA, Rama-Iniguez S, Sanchez-Brunete JA, et al. Anti-leishmanial activity of a new formulation of amphotericin B. Trop Med Int Health 2004;9(9):981-90
   PubMed Web of Science ®Google Scholar
• Sanchez-Brunete JA, Dea MA, Rama S, et al. Treatment of experimental visceral leishmaniasis with amphotericin B in stable albumin microspheres. Antimicrob Agents Chemother 2004;48(9):3246-52
   PubMed Web of Science ®Google Scholar
• Rama Iniguez S, Dea-Ayuela MA, Sanchez-Brunete JA, et al. Real-time reverse transcription-PCR quantification of cytokine mRNA expression in golden Syrian hamster infected with Leishmania infantum and treated with a new amphotericin B formulation. Antimicrob Agents Chemother 2006;50(4):1195-201
   PubMed Web of Science ®Google Scholar
• Khan W, Kumar N. Drug targeting to macrophages using paromomycin-loaded albumin microspheres for treatment of visceral leishmaniasis: an in vitro evaluation. J Drug Target 2011;19(4):239-50
   PubMed Web of Science ®Google Scholar
• Nahar M, Dubey V, Mishra D, et al. In vitro evaluation of surface functionalized gelatin nanoparticles for macrophage targeting in the therapy of visceral leishmaniasis. J Drug Target 2010;18(2):93-105
   PubMed Web of Science ®Google Scholar
• Asthana S, Jaiswal AK, Gupta PK, et al. Immunoadjuvant chemotherapy of visceral leishmaniasis in hamsters using amphotericin B-encapsulated nanoemulsion template-based chitosan nanocapsules. Antimicrob Agents Chemother 2013;57(4):1714-22
   PubMed Web of Science ®Google Scholar
• Kunjachan S, Gupta S, Dwivedi AK, et al. Chitosan-based macrophage-mediated drug targeting for the treatment of experimental visceral leishmaniasis. J Microencapsul 2011;28(4):301-10
   PubMed Web of Science ®Google Scholar
• Singodia D, Khare P, Dube A, et al. Development and performance evaluation of alginate-capped amphotericin B lipid nanoconstructs against visceral leishmaniasis. J Biomed Nanotechnol 2011;7(1):123-4
   PubMed Web of Science ®Google Scholar
• Baillie AJ, Coombs GH, Dolan TF, et al. Biodegradable microspheres: polyacryl starch microparticles as a delivery system for the antileishmanial drug, sodium stibogluconate. J Pharm Pharmacol 1987;39(10):832-5
   PubMed Web of Science ®Google Scholar
• Degling L, Stjarnkvist P, Sjoholm I. Interferon-gamma in starch microparticles: nitric oxide-generating activity in vitro and antileishmanial effect in mice. Pharm Res 1993;10(6):783-90
   PubMed Web of Science ®Google Scholar
• Laakso T, Stjarnkvist P, Sjoholm I. Biodegradable microspheres. VI: lysosomal release of covalently bound antiparasitic drugs from starch microparticles. J Pharm Sci 1987;76(2):134-40
   PubMed Web of Science ®Google Scholar
• Medda S, Mukhopadhyay S, Basu MK. Evaluation of the in-vivo activity and toxicity of amarogentin, an antileishmanial agent, in both liposomal and niosomal forms. J Antimicrob Chemother 1999;44(6):791-4
   PubMed Web of Science ®Google Scholar
• Sarkar S, Mandal S, Sinha J, et al. Quercetin: critical evaluation as an antileishmanial agent in vivo in hamsters using different vesicular delivery modes. J Drug Target 2002;10(8):573-8
   PubMed Web of Science ®Google Scholar
• Sinha J, Raay B, Das N, et al. Bacopasaponin C: critical evaluation of anti-leishmanial properties in various delivery modes. Drug Deliv 2002;9(1):55-62
   PubMed Web of Science ®Google Scholar
• Basu MK, Lala S. Macrophage specific drug delivery in experimental leishmaniasis. Curr Mol Med 2004;4(6):681-9
   PubMed Web of Science ®Google Scholar
• Kobets T, Grekov I, Lipoldova M. Leishmaniasis: prevention, parasite detection and treatment. Curr Med Chem 2012;19(10):1443-74
   PubMed Web of Science ®Google Scholar
• Kedzierski L, Zhu Y, Handman E. Leishmania vaccines: progress and problems. Parasitology 2006;133(Suppl):S87-112
   PubMedGoogle Scholar
• O'Hagan DT, Rahman D, McGee JP, et al. Biodegradable microparticles as controlled release antigen delivery systems. Immunology 1991;73(2):239-42
   PubMed Web of Science ®Google Scholar
• Badiee A, Heravi Shargh V, Khamesipour A, et al. Micro/nanoparticle adjuvants for antileishmanial vaccines: present and future trends. Vaccine 2013;31(5):735-49
   PubMed Web of Science ®Google Scholar
• Kensil CR, Mo AX, Truneh A. Current vaccine adjuvants: an overview of a diverse class. Front Biosci 2004;9:2972-88
   PubMed Web of Science ®Google Scholar
• Tafaghodi M, Eskandari M, Kharazizadeh M, et al. Immunization against leishmaniasis by PLGA nanospheres loaded with an experimental autoclaved Leishmania major (ALM) and Quillaja saponins. Trop Biomed 2010;27(3):639-50
   PubMed Web of Science ®Google Scholar
• Tafaghodi M, Khamesipour A, Jaafari MR. Immunization against leishmaniasis by PLGA nanospheres encapsulated with autoclaved Leishmania major (ALM) and CpG-ODN. Parasitol Res 2011;108(5):1265-73
   PubMed Web of Science ®Google Scholar
• Tafaghodi M, Eskandari M, Khamesipour A, et al. Alginate microspheres encapsulated with autoclaved Leishmania major (ALM) and CpG-ODN induced partial protection and enhanced immune response against murine model of leishmaniasis. Exp Parasitol 2011;129(2):107-14
   PubMed Web of Science ®Google Scholar
• Danesh-Bahreini MA, Shokri J, Samiei A, et al. Nanovaccine for leishmaniasis: preparation of chitosan nanoparticles containing Leishmania superoxide dismutase and evaluation of its immunogenicity in BALB/c mice. Int J Nanomedicine 2011;6:835-42
   PubMed Web of Science ®Google Scholar
• Basu R, Bhaumik S, Basu JM, et al. Kinetoplastid membrane protein-11 DNA vaccination induces complete protection against both pentavalent antimonial-sensitive and -resistant strains of Leishmania donovani that correlates with inducible nitric oxide synthase activity and IL-4 generation: evidence for mixed Th1- and Th2-like responses in visceral leishmaniasis. J Immunol 2005;174(11):7160-71
   PubMed Web of Science ®Google Scholar
• Santos DM, Carneiro MW, de Moura TR, et al. Towards development of novel immunization strategies against leishmaniasis using PLGA nanoparticles loaded with kinetoplastid membrane protein-11. Int J Nanomedicine 2012;7:2115-27
   PubMedGoogle Scholar
• Ashutosh Sundar S, Goyal N. Molecular mechanisms of antimony resistance in Leishmania. J Med Microbiol 2007;56(Pt 2):143-53
   PubMed Web of Science ®Google Scholar
• Denton H, McGregor JC, Coombs GH. Reduction of anti-leishmanial pentavalent antimonial drugs by a parasite-specific thiol-dependent reductase, TDR1. Biochem J 2004;381(Pt 2):405-12
   PubMedGoogle Scholar
• Kandpal M, Fouce RB, Pal A, et al. Kinetics and molecular characteristics of arginine transport by Leishmania donovani promastigotes. Mol Biochem Parasitol 1995;71(2):193-201
   PubMed Web of Science ®Google Scholar
• Carvalho L, Luque-Ortega JR, Lopez-Martin C, et al. The 8-aminoquinoline analogue sitamaquine causes oxidative stress in Leishmania donovani promastigotes by targeting succinate dehydrogenase. Antimicrob Agents Chemother 2011;55(9):4204-10
   PubMed Web of Science ®Google Scholar
• Basselin M, Denise H, Coombs GH, et al. Resistance to pentamidine in Leishmania mexicana involves exclusion of the drug from the mitochondrion. Antimicrob Agents Chemother 2002;46(12):3731-8
   PubMed Web of Science ®Google Scholar
• Zhai L, Chen M, Blom J, et al. The antileishmanial activity of novel oxygenated chalcones and their mechanism of action. J Antimicrob Chemother 1999;43(6):793-803
   PubMed Web of Science ®Google Scholar
• Torres-Santos EC, Sampaio-Santos MI, Buckner FS, et al. Altered sterol profile induced in Leishmania amazonensis by a natural dihydroxymethoxylated chalcone. J Antimicrob Chemother 2009;63(3):469-72
   PubMed Web of Science ®Google Scholar
• Tasdemir D, Kaiser M, Brun R, et al. Antitrypanosomal and antileishmanial activities of flavonoids and their analogues: in vitro, in vivo, structure-activity relationship, and quantitative structure-activity relationship studies. Antimicrob Agents Chemother 2006;50(4):1352-64
   PubMed Web of Science ®Google Scholar
• Georgopoulou K, Smirlis D, Bisti S, et al. In vitro activity of 10-deacetylbaccatin III against Leishmania donovani promastigotes and intracellular amastigotes. Planta Med 2007;73(10):1081-8
   PubMed Web of Science ®Google Scholar
• Fournet A, Angelo A, Munoz V, et al. Biological and chemical studies of Pera benensis, a Bolivian plant used in folk medicine as a treatment of cutaneous leishmaniasis. J Ethnopharmacol 1992;37(2):159-64
   PubMed Web of Science ®Google Scholar
• Germonprez N, Maes L, Van Puyvelde L, et al. In vitro and in vivo anti-leishmanial activity of triterpenoid saponins isolated from Maesa balansae and some chemical derivatives. J Med Chem 2005;48(1):32-7
   PubMed Web of Science ®Google Scholar
• Banerjee G, Bhaduri AN, Basu MK. Mannose-coated liposomal hamycin in the treatment of experimental leishmaniasis in hamsters. Biochem Med Metab Biol 1994;53(1):1-7
   PubMedGoogle Scholar
• Lala S, Pramanick S, Mukhopadhyay S, et al. Harmine: evaluation of its antileishmanial properties in various vesicular delivery systems. J Drug Target 2004;12(3):165-75
   PubMed Web of Science ®Google Scholar
• Medda S, Jaisankar P, Manna RK, et al. Phospholipid microspheres: a novel delivery mode for targeting antileishmanial agent in experimental leishmaniasis. J Drug Target 2003;11(2):123-8
   PubMed Web of Science ®Google Scholar
• Ordonez-Gutierrez L, Espada-Fernandez R, Dea-Ayuela MA, et al. In vitro effect of new formulations of amphotericin B on amastigote and promastigote forms of Leishmania infantum. Int J Antimicrob Agents 2007;30(4):325-9
   PubMed Web of Science ®Google Scholar